New Covid Vaccine Approved - But Not For Everyone
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources.
Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content.
The United States Food and Drug Administration (FDA) has approved another vaccine maker to create a shot to help prevent COVID-19, with caveats.
Newsweek has reached out to Novavax for a statement over email Sunday during non-working hours.
Why It Matters
COVID-19, the disease is caused by the SARS-CoV-2 virus, swept through the world in early 2020, causing lockdowns, hospitalization spikes, and millions of deaths.
Over seven million people have died from COVID-19 globally since the start of the pandemic in 2020, according to the World Health Organization (WHO).
Out of the 7,095,349 deaths worldwide, 1,223,101 are in the US alone, the most recorded COVID-19 deaths of any country, according to WHO.
What To Know
Novavax's vaccine - Adjuvanted -is approved only for those aged 65 and older or people aged 12 to 65 "who have at least one underlying condition that puts them at high risk for severe outcomes from COVID-19", according to a letter from the FDA released Friday.
"We are confident our well-tolerated vaccine represents an important alternative to mRNA COVID-19 vaccines for the U.S.," a press release from the company issued when they entered the vaccine for approval in April read.
This vaccine did previously have emergency approval by the FDA for use but can now be marketed in the U.S. for use, the letter said.
The approval comes amid Robert Kennedy Jr.'s appointment as United States Secretary of Health and Human Services. He has been outspoken about his distrust of medicinal treatments, including vaccines.
Novavax makes the only protein-based COVID-19 vaccine, which operates differently from other vaccines that use messenger RNA (mRNA).
Those mRNA vaccines prompt the patient to produce small amounts of virus to help create an immune response while the Adjuvanted has a protein spike to create the coupled with a Matrix-M adjuvant to prompt an immune response.
The company submitted its product for approval on April 1 along with Phase 3 clinical trial data, the press release said.
Development of the Novavax COVID-19 vaccine has been ongoing since 2020.
A general view of Novavax vaccine vials as the Dutch Health Service Organization starts with the Novavax vaccination program on March 21, 2022 in The Hague, Netherlands.
A general view of Novavax vaccine vials as the Dutch Health Service Organization starts with the Novavax vaccination program on March 21, 2022 in The Hague, Netherlands.
Photo by PatrickData from the United States Centers for Disease Control and Prevention (CDC) shows that vaccines have had overall benefits including a decrease in hospitalization of about one third among adults with weakened immune systems.
What People Are Saying
Dr. Paul Offit, Director of the Vaccine Education Center and professor of pediatrics in the Division of Infectious Diseases at Children's Hospital of Philadelphia told The New York Times: "I think the goal of Robert F. Kennedy Jr. is to make vaccines less available, more expensive, and more feared."
Michael Lin, MD PhD, Professor of Neurobiology & Bioengineering at Stanford University said in part on X, formerly Twitter: "Now the FDA added some odd condition that the vaccine is for those with conditions that increase risk of COVID complications. Given its better safety, it seems backward to put this on Novavax and not the RNA vaccines. But I'd hope you'd be allowed to self declare."
What Happens Next
Now that the FDA has approved, the CDC will have to release guidance on usage. Additionally, Novavax is required to provide data on people who receive the vaccine, including rates of myocarditis.
Clinical trials of the vaccine are still being done for different age groups.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
There's a new blood test for Alzheimer's. Here's everything you need to know.
When you buy through links on our articles, Future and its syndication partners may earn a commission. The U.S. Food and Drug Administration (FDA) recently cleared a blood test that detects signs of Alzheimer's disease in the brain, according to multiple studies. This is the first-ever blood test available for this common form of dementia. Here's how the new blood test works and why it could be useful to patients. Alzheimer's disease is on the rise, in part because the age group most prone to dementia is growing larger. In the U.S., an estimated 7.2 million Americans ages 65 and older are living with Alzheimer's dementia in 2025. The percentage of affected people increases with age: About 5% of people ages 65 to 74 have Alzheimer's, compared with more than 33% of people ages 85 and older. At the point when a doctor has verified that a patient has cognitive decline, the blood test can be used in place of standard tests to see if they likely have Alzheimer's. Previously, gold-standard methods of diagnosing Alzheimer's have been more invasive and expensive, involving positron emission tomography (PET) scans, which use radioactive substances; and lumbar punctures, (also called spinal taps) during which a clinician uses a needle to sample spinal fluid from the low back. Clinicians also sometimes use MRIs or CT scans to rule out other causes of cognitive decline. The new test measures the ratio of two proteins in human blood, and this ratio correlates with the presence or absence of amyloid plaques, a primary sign of Alzheimer's found in the brain. For people experiencing memory lapses that might be due to Alzheimer's, the first step is to see their primary care physician (PCP), who should do a cognitive test. If there are signs of cognitive impairment, the patient would then be referred to a neurologist for an in-depth evaluation. Both dementia specialists and PCPs will be able to order this blood test to help with diagnosis, said Dr. Gregg Day, a neurologist with the Mayo Clinic in Jacksonville, Florida; Day led a study of the blood test published in June in the Journal of the Alzheimer's Association. A study published in 2024 in JAMA found that whether the test was ordered by a PCP or specialist, it was equally accurate at confirming suspected Alzheimer's diagnoses. PCPs could use the test results to decide whether to refer patients to a specialist, who could prescribe treatments such as lecanemab or donanemab, Day said. Or the PCP could personally prescribe a medicine like donepezil, which can help improve mental function in Alzheimer's. With FDA clearance, Medicare and private health insurance providers alike are expected to cover the new blood test, Day said. The test — called the "Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio" — is intended for people ages 55 and older who show signs and symptoms of cognitive decline that have been confirmed by a clinician. The test is designed for the early detection of amyloid plaques associated with Alzheimer's disease. (Amyloid plaques are unusual clumps found between brain cells and made up of a type of protein called beta-amyloid.) Related: Man nearly guaranteed to get early Alzheimer's is still disease-free in his 70s — how? Early detection is important, said Dr. Sayad Ausim Azizi, clinical chief of behavioral neurology and memory disorders at the Yale School of Medicine. That's because the Alzheimer's brain is like a rusty engine — the plaque is like rust settling onto the engine, interfering with the wheels' ability to turn, Azizi told Live Science. There are FDA-approved treatments that act like oil, helping the wheels to turn, but the medication does not remove the rust itself, he said. Available therapies can slow down the degradation of the brain by about 30% to 40%, studies show, so the patient can retain function for longer. "If you're driving now and living independently and you don't take the medicine, it's likely in five years you won't be able to do all these things," Azizi said, providing a hypothetical example. "If you take the medicine, the five years are extended to eight." If adopted as intended, the new blood test could help more people access these treatments sooner. The test is not recommended for the purposes of screening the general population. It is intended only for people who have been found by a doctor to exhibit signs of Alzheimer's disease, Day and Azizi emphasized. Some amount of amyloid is present in the brain during healthy aging, so its presence doesn't guarantee someone will later have Alzheimer's. If the test detects signs of amyloid plaques 20 years before any cognitive symptoms surface, Azizi explained, it would not make sense to treat the patient at that time. "The treatments are not 100% benign," he added. To receive lecanemab, for example, patients must be able to receive an infusion every two weeks at first and every four weeks later on; donanemab is given every four weeks. Both medications can come with infusion-related reactions, such as headache, nausea and vomiting. Rarely, the treatment donanemab can cause life-threatening allergic reactions, and both lecanemab and donanemab have been tied to rare cases of brain swelling or bleeding in the brain. These latter side effects are related to "amyloid-related imaging abnormalities," which are structural abnormalities that appear on brain scans. The new test can give false positives, meaning a person can potentially test positive when they don't actually have Alzheimer's. That's because the signs of amyloid that the tests look for can be tied to other conditions. For instance, amyloid buildup in the brain could be a sign the kidneys are not functioning optimally, Day said, so he recommends also doing a blood test for kidney function when ordering the Alzheimer's blood test. The Mayo Clinic study included about 510 people, 246 of whom showed cognitive decline; the blood test confirmed 95% of those with cognitive symptoms had Alzheimer's. About 5.3% of cases showed a false negative on the blood test, while 17.6% of cases gave a false positive, Day said. Most of the false-positive patients still had Alzheimer's-like changes in their brains, but their symptoms were ultimately attributed to other diseases, such as Lewy body dementia, Day said. The Mayo study found that the blood test helped doctors distinguish Alzheimer's from these other forms of dementia. As is true of many clinical trials, evaluations of the test have primarily included populations that are healthier than average, Day said. These individuals are not only healthier at baseline, but are more likely to have health insurance and be white and non-Hispanic. So when the blood test is used in a broader population, there may be people with sleep apnea or kidney disease who test positive despite not having Alzheimer's, Day said. Some people with these health problems may also experience memory issues or cognitive impairment that's not caused by Alzheimer's disease. If the blood test points to amyloid buildup, doctors could order additional tests and ask patients about their sleep to help rule out these other possibilities. RELATED STORIES —Could vaccines prevent and treat Alzheimer's disease? —Study unravels whole new layer of Alzheimer's disease —Alzheimer's comes in at least 5 distinct forms, study reveals The test will give researchers a more precise idea of how a patient's clinical symptoms relate to the findings on their blood test, Azizi said. "It's a great way of using a biomarker [measurable sign of disease] in the blood to make an earlier diagnosis to give a drug" to slow disease progression, he said. Azizi added that this blood test could help track whether a treatment for Alzheimer's disease is working, which would be useful both for patients receiving approved medicines and those in trials of new drugs. Looking forward, researchers will also be able to evaluate how well blood-based testing works in more diverse populations, Day noted. This article is for informational purposes only and is not meant to offer medical advice.
Yahoo
2 hours ago
- Yahoo
Richton Park nursing home must pay $5.5 million in wrongful death lawsuit
More than four years after 85-year-old Sandy Brooks died under the care of Landmark of Richton Park Rehabilitation and Nursing Center, his family received news that a jury awarded them $5.5 million in a wrongful death lawsuit brought on his behalf. Brooks was an honest, hardworking husband, father and grandfather who wore his heart on his sleeve, said his daughter Andrea Brooks, 59. Though he had end-stage renal disease that required he receive dialysis three times per week, Andrea said Brooks was generally healthy and lived independently with his wife, Barbara, until he experienced a traumatic fall in October 2020 while watering plants outdoors at their South Side home. Brooks faced intensive treatment for a brain bleed at Advocate Christ Medical Center and made progress before being transferred to Landmark for physical therapy Nov. 25, Andrea Brooks said. 'We were expecting him to come home, because (doctors) were like, 'oh, he just needs therapy, and then from there he should be OK,'' Brooks said. Although COVID-19 era lockdowns remained in effect, Andrea Brooks said family members were able to regularly visit her dad at the hospital. That changed when he was admitted to Landmark, where he stayed for 13 days before he died after, according to the lawsuit, caregivers neglected to give him his required dialysis. 'We were not able to have any phone calls, there was no communication,' Brooks said. 'Nobody was updating us on anything.' Sandy's wife, Barbara, contacted the nursing home up to 10 times per day, rarely receiving responses, Andrea said. On Dec. 6, the family was allowed a brief FaceTime call with Sandy, who was unable to speak, she said, and he was found unresponsive in his room the next day. Sandy missed five dialysis appointments while under the care of Landmark, his family would later discover, prompting their lawsuit that concluded May 30. 'It appears that they were providing him some very basic care,' the family's attorney, Madison Cogan, said Friday. 'And by that, I mean they were going into his room, as far as we can tell. But as far as getting dialysis, that never happened, and I think that is what makes this so egregious. All it took is one nurse to recognize that Sandy needed his dialysis and that he wasn't receiving it.' A jury agreed, holding Landmark and its management company, Infinity Healthcare Management of Illinois LLC, accountable for $5.5 million in damages for neglecting Brooks, whose need for dialysis was chronicled by the hospital where he was previously treated. Landmark of Richton Park did not return messages requesting comment. Cogan said the family had sought between $6 million and $8 million. 'It's really hard to put a number on a life,' she said. Andrea said nothing has been the same since she lost her dad. 'This case, it made me relive everything,' she said. 'I could not believe the magnitude of how my dad suffered, and it just hurt me. It broke my heart that someone could just not care or not do their job.' ostevens@
Yahoo
2 hours ago
- Yahoo
Your Favorite Herb Could Soon Become a Key Treatment for Alzheimer's
Scientists have engineered diAcCA, a stable oral drug derived from carnosic acid in rosemary, intended to combat Alzheimer's by reducing inflammation and oxidative stress in the brain. In preclinical mouse studies, diAcCA has restored memory function, increased synaptic density, and reduced key Alzheimer's biomarkers, including amyloid-β and phosphorylated-tau proteins. The drug activates solely in inflamed brain areas and uses a compound already deemed safe by the FDA, potentially streamlining the path to human clinical trials and allowing for combination use with existing research shows that rosemary has more benefits than just enhancing the aroma and flavor of your next roast. It turns out that it may also serve as a secret ingredient in the fight against Alzheimer's disease, too. In February, researchers from The Scripps Research Institute published findings from their study on a new compound called diAcCA, which they designed as an oral medication that could one day hopefully help treat Alzheimer's disease. As the researchers explain, diAcCA is derived from carnosic acid (CA), a natural antioxidant found in rosemary and sage, which is already known to reduce inflammation and oxidative stress—two factors strongly linked to Alzheimer's progression in previous studies. The authors explained in a statement that carnosic acid works by activating enzymes in the body's "natural defense system." In its purest state, this acid is too unstable to serve as a viable drug therapy. However, they managed to create a stable form known as diAcCA, which they noted, once consumed, converts to carnosic acid in the gut and is then absorbed into the bloodstream. Their work, published in the journal Antioxidants, demonstrated that in mouse models, diAcCA could deliver therapeutic doses of carnosic acid to the brain, resulting in improved "memory and synaptic density." Their analysis also revealed a significant decrease in inflammation in the brain following treatment. 'By combating inflammation and oxidative stress with this diAcCA compound, we actually increased the number of synapses in the brain,' Stuart Lipton, MD, PhD, senior author and professor at Scripps, shared. 'We also took down other misfolded or aggregated proteins such as phosphorylated-tau and amyloid-β, which are thought to trigger Alzheimer's disease and serve as biomarkers of the disease process.' And perhaps most compelling of all, the scientists noted that the drug is activated solely by the inflammation it targets, making it active only in areas of the brain that combat inflammatory damage, thereby limiting side effects. Related: Regularly Eating Breakfast Could Shield You Against Age-Related Brain Changes, Study Finds 'We did multiple different tests of memory, and they were all improved with the drug,' Lipton added. 'And it didn't just slow down the decline; it improved virtually back to normal.' There's also more good news for these researchers. They noted that carnosic acid is already listed on the US Food and Drug Administration's 'generally regarded as safe' (GRAS) list, which could make clinical trials involving humans easier to conduct, as the ingredient itself wouldn't require additional FDA approval. According to Lipton, DiAcCA has the potential to work well in tandem with other Alzheimer's treatments, adding that 'it could make existing amyloid antibody treatments work better by taking away or limiting their side effects." He is not stopping at Alzheimer's, though. Lipton hopes to explore its use for other inflammatory disorders, including type 2 diabetes, heart disease, and Parkinson's disease in the future as well. Read the original article on Food & Wine
